Authors
Latest:
Strategic Realignment for a Better Future 1In adjusting to the long-term aftershocks from the coronavirus pandemic, pharma companies will need to focus on change in three core areas.
Latest:
The Future of Personalized Medicine Hinges on Pharma Executives Revolutionizing Business ModelsThe era of big pharma as product-first companies must end, as services become the larger priority.
Latest:
The Growth of International Arbitration in the Life Sciences SectorIn an unpredictable world, international life sciences collaborations can lead to misunderstandings and enforcement challenges, making an effective dispute resolution mechanism an essential risk management tool.
Latest:
Efficacy Controversy Hits European COVID-19 Vaccine RolloutDonald Macarthur and Dr. Meriem Bouslouk-Marx discuss post-approval findings of national committees in Europe charged with deciding the best strategy to use a new COVID-19 vaccine in their populations.
Latest:
The Need for Digital CME for Physicians Treating Patients with CLLIn the rapidly changing fields of medicine, such as hematology/oncology and specifically with respect to the management of patients with chronic lymphocytic leukemia (CLL), education is a key component of keeping clinicians current on changes to treatment paradigms.
Latest:
To Build AI Maturity, Start With Quick WinsCompanies must determine the right ways to utilize AI.
Latest:
The Importance of Collaborative Business Models for Drug DevelopmentInsights and examples of how collaborative efforts can lead to the development of innovative therapies that target unmet patient needs.
Latest:
Dynamic Compliance: The Best Defense for PharmaA proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.
Latest:
How Agile Practices Can Enable Faster, Better Digital Health ProductsProviding ultimate value to stakeholders remains key in new style of development.
Latest:
As Pharma Continues to Adapt to AI, the POSA Standard will Need to Equally AdaptU.S. patent law will have to adapt to the use of AI in the life sciences industry.
Latest:
How Regulatory Affairs Is Shaping Tomorrow’s Innovation LandscapeAs regulatory reform continues to evolve in the US and Europe, the role of regulatory affairs is poised to help shape the more personalized treatment landscape on the horizon.
Latest:
Building Pharma and Lab Spaces in New Jersey 2021–Adapting to Changing NeedsNJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.
Latest:
Making the Case for Early-Stage Commercial AnalyticsAnalytics capabilities are no longer a nice-to-have, but a necessity to build and maintain a successful business and competitive edge.
Latest:
Q&A with Amy West, Head of US Digital Health & Innovation Strategy at Novo NordiskAmy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk, shares her insights on fostering collaboration, embracing change, and her compelling vision to revolutionize digital transformation and innovation in the field of healthcare.
Latest:
Health Tech Companies Lead Charge for Greater AccessStay-at-home orders during the pandemic forced a shift in patient preferences—and the pharma industry has responded.
Latest:
HCPs & Virtual Meetings: What We LearnedAddressing the challenges created by virtual meetings with HCPs, what we have learned about virtual meetings so far, and a look into the future.
Latest:
Addressing the Knowledge Gap in Biologics & Biosimilars: Is a Board Certified Biologics and Biosimilars Program the Answer?Life sciences professionals will need to keep up with market demand for biologics and biosimilars.
Latest:
Delivering Brand Relevancy through Connected Data and AnalyticsHow a large, global biopharma company is leveraging a data-linking strategy to power insight-generation tools and techniques—and supporting customers through their journey with dynamic personalization and modular content.
Latest:
Are You Up to Date With the Latest FDA Guidance?Webinar Date/Time: Tue, Nov 19, 2024 11:00 AM EST
Latest:
Delivering Medical Affairs Value Through Omnichannel OrchestrationLearnings from a roundtable discussion with Medical Affairs leadership from 11 pharma companies
Latest:
Harnessing the Value of AI In Customer EngagementBy using correct data and pertinent ML algorithms, customer engagement leaders can identify deep insights into customer behavior and make the right interventions to transform the customer experience.
Latest:
Building an Optimal Patient Support TeamHow effective training programs enable ‘next-generation’ patient engagement.
Latest:
Using Identity Resolution Technology to Dispense Hyper-Relevant Information to HCPsHealthcare professionals (HCPs) shouldn’t miss out on critical information while their focus is on their patients, which is why messages on professional platforms are an essential resource to improve a patient’s health results, writes Gareth Shaw.
Latest:
Boosting Clinical Trials and Patient Access with Payer InsightsClinical studies are increasingly designed to satisfy evidentiary needs.
Latest:
Delivery and Disruption: Navigating a Changing Care TerrainThe diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.
Latest:
Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime ValuePresenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.
